A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment
Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
This is a study where AZD5213 or placebo is given to patients with Mild Alzheimer's Disease
or Mild Cognitive Impairment in a blinded and random assignment. The main study objective is
to estimate the relationship of sleep duration versus dose after 4 weeks of treatment.